|
Fig. 4 Targets identification of ZGS II, BA, and DMA against leukopenia through network pharmacology. (A) ZGSII/BA/DMA-leukopenia-target networks. (B) Common targets of the compounds (ZGSII, BA, DMA) and leukopenia. (C) Protein-protein interaction (PPI) network of the bioactive compounds against leukopenia. (D) The top 12 biological processes of core targets for ZGSII, DMA, and BA against leukopenia, and (E) the related genes correspond to GO terms. (F-H) RTsingle bondqPCR validation of selected predicted genes (IFN-γ, IL-2, CEBP-β). (I) Western blot analysis and quantification of IFN-γ expression in NB4 cells treated with ZGSⅡ, BA, DMA, or C3G for 5 days. Data represent the mean ± SD of three independent experiments. * p < 0.05, * * p < 0.01, * ** p < 0.001 versus as indicated (one-way analysis of variance). (J) Top 20 enriched KEGG pathways of core targets for ZGSII, BA, and DMA against leukopenia.